Perioperative immunotherapy and chemotherapy for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (sintilimab) and chemotherapy given before and after surgery for esophageal squamous cell carcinoma. The goal is to see if this approach can improve outcomes for patients with resectable tumors in the middle or lower esophagus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma, confirmed by biopsy.
- Your tumor is in the middle or lower part of the esophagus and is considered removable by surgery.
- Your cancer has not spread to other parts of the body (no metastases).
- You are in good overall health (able to care for yourself) and can eat semi-liquid food.
- You have not lost more than 20% of your body weight in the last 6 months.
- You are willing to use effective birth control during treatment and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving the immunotherapy drug Sintilimab after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes and who have already had their tumor removed.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
This trial compares the usual treatment (chemotherapy plus radiation before surgery) with a combination that also includes an immunotherapy drug called sintilimab. The goal is to see if adding immunotherapy helps shrink the tumor and improve outcomes for patients with esophageal cancer that can be removed by surgery.
This study tests a combination of an immunotherapy drug (sintilimab) with chemotherapy given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.